CA3232972A1 - Endoxifen for treatment of cancers - Google Patents

Endoxifen for treatment of cancers Download PDF

Info

Publication number
CA3232972A1
CA3232972A1 CA3232972A CA3232972A CA3232972A1 CA 3232972 A1 CA3232972 A1 CA 3232972A1 CA 3232972 A CA3232972 A CA 3232972A CA 3232972 A CA3232972 A CA 3232972A CA 3232972 A1 CA3232972 A1 CA 3232972A1
Authority
CA
Canada
Prior art keywords
cancer
endoxifen
response
subject
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3232972A
Other languages
English (en)
French (fr)
Inventor
Steven C. Quay
Carla Grandori
Katannya KAPELI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atossa Therapeutics Inc
Original Assignee
Atossa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atossa Therapeutics Inc filed Critical Atossa Therapeutics Inc
Publication of CA3232972A1 publication Critical patent/CA3232972A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3232972A 2021-10-28 2022-10-27 Endoxifen for treatment of cancers Pending CA3232972A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272869P 2021-10-28 2021-10-28
US63/272,869 2021-10-28
PCT/US2022/048061 WO2023076496A1 (en) 2021-10-28 2022-10-27 Endoxifen for treatment of cancers

Publications (1)

Publication Number Publication Date
CA3232972A1 true CA3232972A1 (en) 2023-05-04

Family

ID=86158538

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3232972A Pending CA3232972A1 (en) 2021-10-28 2022-10-27 Endoxifen for treatment of cancers

Country Status (10)

Country Link
US (1) US20250041245A1 (cg-RX-API-DMAC7.html)
EP (1) EP4422608A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024541900A (cg-RX-API-DMAC7.html)
KR (1) KR20240093500A (cg-RX-API-DMAC7.html)
CN (1) CN118159259A (cg-RX-API-DMAC7.html)
AU (1) AU2022378576A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232972A1 (cg-RX-API-DMAC7.html)
IL (1) IL312037A (cg-RX-API-DMAC7.html)
MX (1) MX2024005220A (cg-RX-API-DMAC7.html)
WO (1) WO2023076496A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022232924A1 (en) * 2021-03-11 2023-07-06 Atossa Therapeutics, Inc. Endoxifen for treatment of ovarian cancer
CN117338780A (zh) * 2023-09-21 2024-01-05 中国人民解放军海军军医大学 帕罗西汀在制备抗肿瘤药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033430A1 (en) * 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
CN104334170B (zh) * 2011-11-04 2020-02-07 迈伦·R·谢夫丘克 Neu1唾液酸酶抑制剂在癌症治疗中的用途
DE102015222031A1 (de) * 2015-11-10 2017-05-11 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (Z)-Endoxifenhydrochlorid
WO2017127442A1 (en) * 2016-01-18 2017-07-27 The Regents Of The University Of California Methods for treating cancer with rorgamma inhibitors
WO2021003433A1 (en) * 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CA3160614A1 (en) * 2019-12-12 2021-06-17 Marcela GUZMAN AYALA Method and compositions for regulated armoring of cells
AU2022232924A1 (en) * 2021-03-11 2023-07-06 Atossa Therapeutics, Inc. Endoxifen for treatment of ovarian cancer
EP4514327A1 (en) * 2022-04-26 2025-03-05 Atossa Therapeutics, Inc. High dose endoxifen formulations and methods of use

Also Published As

Publication number Publication date
IL312037A (en) 2024-06-01
EP4422608A4 (en) 2025-09-24
AU2022378576A1 (en) 2024-03-28
KR20240093500A (ko) 2024-06-24
EP4422608A1 (en) 2024-09-04
US20250041245A1 (en) 2025-02-06
WO2023076496A1 (en) 2023-05-04
CN118159259A (zh) 2024-06-07
JP2024541900A (ja) 2024-11-13
MX2024005220A (es) 2024-05-16

Similar Documents

Publication Publication Date Title
US12281056B2 (en) Methods for making and using endoxifen
US20250041245A1 (en) Endoxifen for treatment of cancers
TW202340135A (zh) (z)—因多昔芬之組合物及其富集方法
AU2026200456A1 (en) Treatment of canine cancers
US20250235451A1 (en) Methods of Delaying Pain Progression And Treating Prostate Cancer
CA3203125A1 (en) Endoxifen for treatment of ovarian cancer
WO2024091551A1 (en) Crystalline forms, pharmaceutical compositions and methods of use thereof
HK40105626A (en) Endoxifen for treatment of cancers
WO2026101937A1 (en) Compositions comprising (z)-endoxifen and a cdk4/6 inhibitor and methods of use thereof
WO2025151443A1 (en) Endoxifen for treatment of rare cancers
HK40031003A (en) Methods for making and using endoxifen

Legal Events

Date Code Title Description
R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20240710

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241010

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241010

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250902

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250902

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260310

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260310

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20260320

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260706

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260706